Search results
7 lip 2018 · Although clinical presentations can vary, there is no cure for ALS, and the disease is universally terminal, with most patients dying of respiratory complications. Patients die, on average, within 3 to 5 years of diagnosis, unless they choose to undergo tracheostomy, in which case, they may live, on average, 2 additional years.
Respiratory Therapy. Amyotrophic lateral sclerosis is a progressive neuromuscular disease characterized by both lower motor neuron and upper motor neuron dysfunction. Although clinical presentations can vary, there is no cure for ALS, and the disease is universally terminal, with most patients dying of respiratory compl …
In this review, we summarize the current state of ALS therapy. We extensively discuss medical as well as supportive therapy options as they are both important aspects of ALS disease management and, in our opinion, inseparable in the current state of ALS treatment.
19 sty 2023 · A comprehensive, multidisciplinary approach to ALS respiratory care may minimize hospitalizations for acute respiratory failure, reduce need for emergent tracheostomy, improve patient-reported outcome measures, and facilitate developing clinical research initiatives.
Follow-up should review treatment options and include regular respiratory monitoring using simple tests, such as: upright and supine vital capacity (VC), maximal inspiratory and expiratory flow rates, oximetry, and peak cough flow (PCF) rate.
Amyotrophic Lateral Sclerosis Neurology Neuromuscular Diseases Critical Care Medicine Respiratory Failure and Ventilation. This Viewpoint describes the dearth of noninvasive ventilation for patients with amyotrophic lateral sclerosis in the US and proposes methods to increase.
Much of the therapy for ALS is directed at improving respiratory symptoms and minimizing pulmonary complications. 9 This therapy includes interventions directed at secretion clearance and ventilator support. This article describes the respiratory evaluation and treatment of individuals with ALS.
